Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CBIO Crescent Biopharma Inc

Trading 07-06 12:17:52 EDT

16.90

-0.19

-1.11%

High17.58	Low16.57	Vol45.00K
Open17.00	D1 Closing17.09	Amplitude5.91%
Mkt Cap465.71M	Tradable Cap183.72M	Total Shares27.56M
T/O757.00K	T/O Rate0.41%	Tradable Shares10.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":16.9,"timestamp":1783354667219,"preClose":17.09,"halted":0,"volume":44998,"delay":0,"changeRate":-0.011117612638970233,"floatShares":10871000,"shares":27556800,"eps":-5.878,"marketStatus":"Trading","change":-0.19,"latestTime":"07-06 12:17:52 EDT","open":17,"high":17.58,"low":16.57,"amount":757001.9389739999,"amplitude":0.059099,"askPrice":16.91,"askSize":2,"bidPrice":16.75,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-5.878,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783368000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":17.09,"preHourTrading":{"tag":"盘前","latestPrice":16.85,"preClose":17.09,"latestTime":"08:26 EDT","volume":112,"amount":1887.2000000000003,"timestamp":1783340790833,"change":-0.24,"changeRate":-0.014043,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":17.09,"preClose":17.09,"latestTime":"16:37 EDT","volume":527,"amount":9006.84,"timestamp":1783024652393,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.124402,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO","defaultTab":"news","newsList":[{"id":"2648752631","title":"Crescent Biopharma - May Offer and Sell up to $500 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2648752631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648752631?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:17","pubTimestamp":1782937038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nFWN43311O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360524","title":"Crescent Biopharma Grants Inducement Stock Options for 65,100 Shares at $16.99 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360524?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:16","pubTimestamp":1782505003,"startTime":"0","endTime":"0","summary":"Crescent Biopharma grants inducement stock options for 65,100 shares at $16.99 eachCrescent Biopharma set inducement equity awards for three non-executive employees, granting options for 65,100 ordina","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLrb8JX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645862835","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645862835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645862835?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:29","pubTimestamp":1782214185,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Crescent Biopharma today and set a price target of $30.00. Willey covers the Heal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-crescent-biopharma-cbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-crescent-biopharma-cbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CBIO","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231782","title":"Crescent Biopharma grants inducement stock options for 23,550 shares at $17.57 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231782?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:16","pubTimestamp":1781209011,"startTime":"0","endTime":"0","summary":"Crescent Biopharma granted options covering 23,550 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.Options carry a 10-year term with an exercise price of USD 17.57, set at the June 10 Nasdaq closing price.Vesting starts with 25% on the first anniversary of each employee’s start date, then monthly in equal installments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLccmM9p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640902669","title":"Crescent Biopharma shareholders elect two Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640902669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640902669?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:03","pubTimestamp":1780491811,"startTime":"0","endTime":"0","summary":"Crescent Biopharma held its annual general meeting on June 2, 2026.Shareholders backed an annual schedule for future advisory votes on executive pay; the board set the vote to occur every year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL5j0Fh7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640925330","title":"Crescent Biopharma to present at Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2640925330","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640925330?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:18","pubTimestamp":1780431519,"startTime":"0","endTime":"0","summary":"Crescent Biopharma will present at the Jefferies Global Healthcare Conference on June 3, 2026 in New York.Management will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 in Miami.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLgWdjs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4552","IE00BSNM7G36.USD","GSX","BK4127","LU0106831901.USD","LU0048573561.USD","LU1668664300.SGD","LU0345770308.USD","LU0868494708.USD","LU0251142724.SGD","LU1868837136.USD","LU0868494617.USD","LU1868836757.USD","LU2471134796.USD","LU2750360641.GBP","IE0004091025.USD","CBIO","LU2471134523.USD","LU2750360997.AUD","LU2265009873.SGD","LU2237443978.SGD","LU1894683348.USD","BK4504","BK4139","BK4516","LU2237443622.USD","LU2237438978.USD","LU2471134879.HKD","IE00B19Z3581.USD","IE0004086264.USD","IE0034235188.USD","BK4533","LU0251131958.USD","LU0061475181.USD","LU0742534661.SGD","LU1868837300.USD","LU1804176565.USD","LU2237443895.HKD","IE00BFXG1179.USD","IE0002270589.USD","LU1894683264.USD","BK4550","LU0345770993.USD","LU2237443549.SGD","LU1868836591.USD","BK4585","LU1868836914.USD","BK4588","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640961543","title":"Crescent Biopharma Shares Fall After HC Wainwright Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2640961543","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640961543?lang=en_us&edition=fundamental","pubTime":"2026-06-02 03:10","pubTimestamp":1780341029,"startTime":"0","endTime":"0","summary":"Crescent Biopharma (CBIO) shares fell 5.4% on Monday after HC Wainwright downgraded the stock to neutral from buy.Trading volume stood at around 254,676 shares compared with a daily average of 264,600.Price: 19.53, Change: -1.12, Percent Change: -5.42","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640241952","title":"Analysts Are Bullish on These Healthcare Stocks: Crescent Biopharma (CBIO), IQVIA Holdings (IQV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640241952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640241952?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:40","pubTimestamp":1780321208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crescent Biopharma (CBIO) and IQVIA Holdings (IQV) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-crescent-biopharma-cbio-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-crescent-biopharma-cbio-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4121","BK4588","LU1989764664.SGD","LU0528227936.USD","LU0130103400.USD","LU1791710400.SGD","LU0648001328.SGD","LU0130518102.USD","LU1791710582.SGD","LU0882574055.USD","LU0648000940.SGD","BK4530","LU0130102774.USD","LU1989764748.USD","LU1201861249.SGD","LU0477156953.USD","LU0980610538.SGD","LU1261432733.SGD","LU1201861165.SGD","LU0198837287.USD","CBIO","LU0477156797.USD","IQV","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959866","title":"Crescent Biopharma Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959866","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959866?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:41","pubTimestamp":1780314060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 07:41 ET (11:41 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953764","title":"Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953764","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953764?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:31","pubTimestamp":1780309879,"startTime":"0","endTime":"0","summary":"H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat thesis is less compe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crescent-biopharma-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crescent-biopharma-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639567200","title":"Crescent Biopharma grants inducement stock options for 16,950 shares at $21.47 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2639567200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639567200?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:19","pubTimestamp":1780085970,"startTime":"0","endTime":"0","summary":"Crescent Biopharma set inducement equity awards for two non-executive hires, granting options covering 16,950 ordinary shares.Options carry a 10-year term with an exercise price of $21.47, set at the May 28 Nasdaq closing price.Vesting starts with 25% on the first anniversary of each employee’s start date, then monthly vesting of the remainder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLbCbRJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638161785","title":"Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638161785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638161785?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:00","pubTimestamp":1779793250,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Crescent Biopharma (CBIO) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-crescent-biopharma-cbio-and-genmab-gmab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-crescent-biopharma-cbio-and-genmab-gmab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LU0029874061.USD","XLV","BK4585","BK4137","XBI","LABU","GMAB","BK4588","CBIO","HCSG","ROIV","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357260","title":"Crescent Biopharma presents ASCEND Phase 1/2 CR-001 trial-in-progress at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357260?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:33","pubTimestamp":1779399221,"startTime":"0","endTime":"0","summary":"Crescent Biopharma will present a trial-in-progress poster at the ASCO 2026 Annual Meeting on May 30 for ASCEND, its Phase 1/2 study of CR-001 in locally advanced or metastatic solid tumors.The program is positioned as an early-stage test of CR-001’s safety profile, dose selection strategy, and initial signs of anti-tumor activity across several tumor settings.Enrollment is ongoing for a global, open-label study expected to include up to 290 patients across dose-escalation, backfill, and dose-optimization cohorts.Initial proof-of-concept readouts are slated to begin in Q1 2027, with additional updates on combinations with standard chemotherapy or an antibody-drug conjugate planned for mid-2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8TYL5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357465","title":"Crescent Biopharma Announces Trial in Progress Presentation for Ascend Study of Cr-001, a Pd-1 X Vegf Bispecific Antibody, at Upcoming American Society of Clinical Oncology (Asco) 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357465?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:30","pubTimestamp":1779399000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA15RP3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635805228","title":"Crescent Biopharma grants inducement stock options for 129,075 shares at $18.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2635805228","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635805228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:36","pubTimestamp":1778618173,"startTime":"0","endTime":"0","summary":"Crescent Biopharma granted stock options covering 129,075 ordinary shares to five non-executive employees under its 2025 Employment Inducement Incentive Award Plan.Options carry 10-year terms with exercise price set at $18.52, equal to Nasdaq closing price on May 11, 2026.Vesting schedule sets 25% on first anniversary of each employee’s start date, then 1/48 monthly vesting thereafter, subject to continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5gM9R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633148129","title":"Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=2633148129","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633148129?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:39","pubTimestamp":1778150360,"startTime":"0","endTime":"0","summary":"Shareholders in Crescent Biopharma, Inc. ( NASDAQ:CBIO ) may be thrilled to learn that the analysts have just delivered...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cbio/crescent-biopharma/news/rainbows-and-unicorns-crescent-biopharma-inc-nasdaqcbio-anal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cbio/crescent-biopharma/news/rainbows-and-unicorns-crescent-biopharma-inc-nasdaqcbio-anal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","IYW","QQQY","TQQY","QLD","NVIW.SI","QID","BK4139","FTEC","QQQ","ONEQ","QQQJ","QYLG","QDTE","TQQQ","NQmain","SQQQ","GPIQ","QQQM","NDX","MNQmain","JEPQ","CBIO",".IXIC","QQQA","QQQE","TECS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632964592","title":"Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2632964592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632964592?lang=en_us&edition=fundamental","pubTime":"2026-05-01 23:58","pubTimestamp":1777651080,"startTime":"0","endTime":"0","summary":"Crescent Biopharma, Inc.  is currently at $18.77, down $3.60 or 16.09%. --Would be lowest close since April 13, 2026, when it closed at $17.99. --On pace for largest percent decrease since July 25, 2024, when it fell 24.2%. --Down 24.31% this week; worst weekly performance since the week ending Jan. 30, 2026, when it fell 25.08%. --Down 99.26% from its all-time closing high of $2535.00 on Feb. 15, 2018. --Down 28.25% from 52 weeks ago , when it closed at $26.16. --Up 109.96% from its 52-week closing low of $8.94 on Feb. 13, 2026. --Traded as low as $14.91; lowest intraday level since March 30, 2026, when it hit $14.25. --Down 33.35% at today's intraday low; largest intraday percent decrease since July 25, 2024, when it fell as much as 34.84%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632699402","title":"Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632699402","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632699402?lang=en_us&edition=fundamental","pubTime":"2026-05-01 10:25","pubTimestamp":1777602343,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Crescent Biopharma yesterday and set a price target of $30.00. Willey covers the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-crescent-biopharma-cbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-crescent-biopharma-cbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631952925","title":"Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2631952925","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631952925?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:36","pubTimestamp":1777495008,"startTime":"0","endTime":"0","summary":"Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of $(19.63) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/52153246/crescent-biopharma-q1-eps-0-70-beats-0-98-estimate-sales-1-039m-beat-357-143k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630822028","title":"Crescent Biopharma grants inducement stock options for 12,525 shares at $25.7 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2630822028","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630822028?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:16","pubTimestamp":1777061811,"startTime":"0","endTime":"0","summary":"Crescent Biopharma granted stock options covering 12,525 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.Options carry a 10-year term with an exercise price of $25.70 per share, set at April 23 close.Vesting starts with 25% on first anniversary of start date, then continues monthly at 1/48 of grant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL85j444:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crescentbiopharma.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":0.005},{"period":"3month","weight":-0.1191},{"period":"6month","weight":0.5424},{"period":"1year","weight":0.0994},{"period":"ytd","weight":0.441}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001565},{"month":2,"riseRate":0.615385,"avgChangeRate":0.005722},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.009855},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.042062},{"month":5,"riseRate":0.461538,"avgChangeRate":0.07932},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.030953},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.057578},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.030216}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}